REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.39
+0.27 (2.96%)
May 4, 2026, 4:00 PM EDT - Market closed
REGENXBIO Market Cap
REGENXBIO has a market cap or net worth of $484.69 million as of May 4, 2026. Its market cap has increased by 57.11% in one year.
Market Cap
484.69M
Enterprise Value
504.35M
1-Year Change
57.11%
Ranking
Category
Stock Price
$9.39
Market Cap Chart
Since September 17, 2015, REGENXBIO's market cap has decreased from $749.30M to $484.69M, a decrease of -35.31%. That is a compound annual growth rate of -4.02%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 1, 2026 | 470.70M | -35.43% |
| Dec 31, 2025 | 729.00M | 90.34% |
| Dec 31, 2024 | 383.00M | -51.50% |
| Dec 29, 2023 | 789.70M | -19.57% |
| Dec 30, 2022 | 981.90M | -29.79% |
| Dec 31, 2021 | 1.40B | -17.57% |
| Dec 31, 2020 | 1.70B | 12.32% |
| Dec 31, 2019 | 1.51B | 0.48% |
| Dec 31, 2018 | 1.50B | 45.18% |
| Dec 29, 2017 | 1.04B | 110.87% |
| Dec 30, 2016 | 491.10M | 12.43% |
| Dec 31, 2015 | 436.80M | -41.71% |
| Sep 17, 2015 | 749.30M | - |
View and export this data all the way back to 2015. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Immix Biopharma | 504.68M |
| Lyell Immunopharma | 494.65M |
| XOMA Royalty | 493.55M |
| Eupraxia Pharmaceuticals | 487.15M |
| 4D Molecular Therapeutics | 482.18M |
| ADC Therapeutics | 475.05M |
| Fulcrum Therapeutics | 471.76M |
| Sagimet Biosciences | 468.70M |